Glennie, Martin - University of Southampton

个人简介

Professor Glennie was appointed a personal chair in 1999 and was Head of the Cancer Sciences Unit from 2005 to 2015. Having graduated from the University of Southampton in 1977, he embarked on a PhD with Profs Freda and George Stevenson investigating the therapeutic application of antibodies to the treatment of cancer. In 1980 he moved to Cambridge to work with Prof Arnold Feinstein on the structure and function of pentameric IgM, before returning to Southampton to take up a ‘New Blood’ lectureship in cancer immunotherapy. Throughout his career Professor Glennie has focused on understanding and improving how antibodies can be used therapeutically. He was one of the first to undertake antibody engineering and to show that structural changes, such as reducing antibody valency, could have profound benefits on therapeutic efficacy. Prof Glennie now leads a team of clinical and non-clinical scientists and students investigating many aspects of antibody immunotherapy. Understanding antibody biology, including target specificity, effector function, half-life, and agonistic activity in cell signalling, has proved critical in developing clinical reagents. Prof Glennie and colleagues (Profs Cragg, Johnson, Al-Shamkhani and Drs Beers, Davies and White) are particularly focused on the role of Fc receptors (FcR), myeloid cells and tumour environment and how these can be modulated to promote antibody activity. They are also investigating the therapeutic potential of immune stimulating antibodies, which stimulate the body’s anti-cancer immunity to provide long-lasting protection against the disease. These reagents are being developed both in preclinical models and in the clinic in Southampton. Professor Glennie is an adjunct Professor to the Dartmouth Medical School, NH, a visiting Professor at the Scripps Research Institute, CA, and consults for the biotech industry in Europe and the US. He is also a frequent reviewer for a wide range of scientific journals and granting bodies, and sits on review panels and advisory boards for Cancer Research UK and the NIH.

研究领域

In recent years monoclonal antibodies have become front runners in the fight against cancer. The Antibody and Vaccine Group in the Cancer Sciences Unit works on understanding the structure and function of antibodies and uses this mechanistic insight to inform cancer treatments. They focus on two main areas: 1) improving the potency of monoclonal antibodies that target cancer cells directly, via FcR-expressing effector cells and complement activation; and 2) developing immunostimulatory antibodies that promote the body’s immune system to provide long-lasting cancer immunity. These latter reagents are also being developed, in collaboration with colleagues in Southampton, for use in combination with cancer vaccines such as RNA and other adjuvants. The field of immunostimulation has been given a major boost by the recent success of anti-PD-1, anti-CTLA-4 and anti-CD40 in ‘difficult to treat’ cancers such as metastatic melanoma.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Obinutuzumab induces superior B-Cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus rrythematosus patient samples - Reddy, Venkat, Klein, Christian, Isenberg, David, Glennie, Martin, Cambridge, Geraldine, Cragg, Mark and Leandro, Maria Published:2016Publication:RheumatologyPage Range:1-25 Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells - Dovedi, Simon, Lipowska-Bhalla, Grazyna, Beers, Stephen A., Cheadle, Eleanor J., Mu, Lijun, Glennie, Martin J., Illidge, Timothy M. and Honeychurch, Jamie Published:2016Publication:Cancer Immunology ResearchVolume:7, (4)Page Range:621-630doi:10.1158/2326-6066.CIR-15-0253PMID:27241845 OX40 regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential - Lai, Chester, August, Suzannah, Albibas, Amel, Behar, Ramnik, Cho, Shin-Young, Polak, Marta, Theaker, Jeff, Macleod, Amanda S., French, Ruth, Glennie, Martin, Al-Shamkhani, Aymen and Healy, Eugene Published:2016Publication:Clinical Cancer ResearchPage Range:1-42doi:10.1158/1078-0432.CCR-15-2614PMID:27034329 Influence of immunoglobulin isotype on therapeutic antibody function - Beers, S., Glennie, M. and White, A. Published:2016Publication:BloodVolume:127, (9)Page Range:1-6doi:10.1182/blood-2015-09-625343PMID:26764357